Skip to main content

Table 3 Comparison of participant characteristics based on diseases present and medication use

From: Effect of oral functional training on immunological abilities of older people: a case control study

Characteristics

Salivary flow (ml/min)

 

Z-Score

P-Value

Ajusted P-Value

IgA concentration (μg/ml)

 

Z-Score

P-Value

Ajusted P-Value

IgA secretion rate (μg/min)

 

Z-Score

P-Value

Ajusted P-Value

without/no use

with/use

without/no use

with/use

without/no use

with/use

 

Average ± S.D.

n

Average ± S.D.

n

Average ± S.D.

n

Average ± S.D.

n

Average ± S.D.

n

Average ± S.D.

n

Diabetes

0.54 ± 0.11

21

0.56 ± 0.23

2

0.273

0.74

 

0.81

 

87.0 ± 44.6

21

122 ± 14.7

2

1.36

0.16

 

0.52

 

50.8 ± 30.9

21

66.8 ± 19.6

2

0.927

0.33

 

0.52

 

Hypertension

0.51 ± 0.13

14

0.58 ± 0.084

9

1.23

0.21

 

0.50

 

81.8 ± 42.7

14

103 ± 45.0

9

1.10

0.26

 

0.52

 

46.0 ± 29.7

14

62.0 ± 29.7

9

1.291

0.19

 

0.52

 

Parkinson’s disease

0.52 ± 0.11

21

0.69 ± 0.03

2

2.02

0.04

*

0.24

 

89.1 ± 44.6

22

112

1

0.678

0.45

 

0.54

 

50.9 ± 30.1

22

80.8

1

0.98

0.29

 

0.54

 

Heart diseases

0.55 ± 0.11

19

0.49 ± 0.03

4

0.771

0.42

 

0.55

 

87.5 ± 37.5

19

102 ± 73.8

4

0.284

0.11

 

0.52

 

51.7 ± 26.8

19

54.9 ± 48.2

4

0.041

0.94

 

0.52

 

Hyperthyroidism

0.54 ± 0.12

22

0.45

1

0.678

0.45

 

0.55

 

89.2 ± 44.7

22

111

1

0.528

0.55

 

0.60

 

52.3 ± 30.8

22

50.4

1

0

1.00

 

0.60

 

Cerebrovascular disease

0.56 ± 0.11

12

0.51 ± 0.13

11

0.954

0.32

 

0.55

 

101 ± 42.9

11

80.2 ± 44.2

12

1.26

0.20

 

0.52

 

56.7 ± 28.8

11

48.1 ± 31.9

12

0.769

0.42

 

0.52

 

Antihypertensive agent

0.54 ± 0.14

8

0.54 ± 0.11

15

0.161

0.85

 

0.85

 

63.1 ± 27.5

8

105 ± 44.8

15

2.03

0.04

*

0.48

 

40.0 ± 24.7

8

58.7 ± 31.4

15

1.323

0.18

 

0.48

 

Diuretics

0.53 ± 0.13

20

0.63 ± 0.053

3

1.90

0.06

 

0.24

 

86.5 ± 39.9

21

127 ± 86.2

2

0.709

0.45

 

0.54

 

49.6 ± 27.2

21

79.6 ± 59.6

2

0.818

0.38

 

0.54

 

Psychotropic drugs

0.55 ± 0.12

19

0.50 ± 0.12

4

0.689

0.46

 

0.55

 

93.6 ± 44.0

19

73.7 ± 45.5

4

0.771

0.42

 

0.54

 

54.6 ± 30.0

19

40.7 ± 31.9

4

0.771

0.42

 

0.54

 

Antidepressants

0.55 ± 0.11

22

0.4

1

0.957

0.34

 

0.55

 

88.2 ± 43.9

22

133

1

0.258

0.23

 

0.52

 

52.2 ± 30.8

22

53

1

0.226

0.76

 

0.52

 

Methyldopa

0.52 ± 0.11

21

0.69 ± 0.034

2

2.02

0.04

*

0.24

 

89.1 ± 44.6

22

112

1

0.678

0.45

 

0.54

 

50.9 ± 30.1

22

80.8

1

0.98

0.29

 

0.54

 

H2 blocker

0.54 ± 0.12

20

0.52 ± 0.12

3

0.320

0.13

 

0.39

 

91.6 ± 45.0

20

80.3 ± 42.2

3

0.320

0.72

 

0.72

 

53.6 ± 31.0

20

43.1 ± 25.9

3

0.411

0.65

 

0.72

 
  1. Note: Participants showing high value ≥ average + 3 × SD were eliminated as outliers (one participant was eliminated for each comparison)
  2. Z-score and P-values were calculated by Wilcoxon rank-sum test (both tailed)
Back to article page

BMC Oral Health

ISSN: 1472-6831

Contact us